In HCC and pancreatic cancer, LHPP binds to the epidermal growth factor receptor (EGFR) and inhibits its phosphorylation, negatively regulating the activation of downstream pathways, including ERK, AKT, and STAT3 [210,211,212], leading to decreased metastatic potential. Here, EGFR is linked to hepatocellular carcinoma.